CN111116490A - Preparation and purification method of oxalagogri intermediate salicylate - Google Patents
Preparation and purification method of oxalagogri intermediate salicylate Download PDFInfo
- Publication number
- CN111116490A CN111116490A CN202010039361.2A CN202010039361A CN111116490A CN 111116490 A CN111116490 A CN 111116490A CN 202010039361 A CN202010039361 A CN 202010039361A CN 111116490 A CN111116490 A CN 111116490A
- Authority
- CN
- China
- Prior art keywords
- salicylate
- solvent
- oxalagril
- dissolving
- acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/48—Separation; Purification; Stabilisation; Use of additives by liquid-liquid treatment
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to the field of pharmacy, in particular to a preparation and purification method of an oxalagril intermediate salicylate, which comprises the following steps: (1) dissolving the crude product of the oxa-goril intermediate in a solvent; (2) dissolving salicylic acid in an alcohol solvent, and then adding the alcohol solvent into the step (1); (3) adding water or an alkane solvent into the step (2), stirring, and cooling to room temperature; (4) separating out solids; (5) dissolving the solid obtained in the step (4) in an ester solvent, adding a phosphoric acid aqueous solution, and extracting to obtain an acid water layer; (6) adding an ester solvent into the acid water layer, adding a sodium hydroxide solution, and extracting and layering to obtain an organic layer; (7) and (4) concentrating and drying the organic layer to obtain a refined product of the intermediate of the oxagoril. According to the invention, the preparation and purification of the oxalagogri intermediate salicylate simplify the production process of subsequent products, reduce the production cost, and are suitable for industrial large-scale production.
Description
Technical Field
The invention relates to the field of pharmacy, and in particular relates to a preparation and purification method of an oxalagril intermediate salicylate.
Background
Endometriosis refers to a common gynecological disease in women, wherein intimal cells are planted in abnormal positions. Ebervia (AbbVie) and the gynecological drug orilisa (elagolix) developed by neurokrine Biosciences are oral gonadotropin releasing hormone (GnRH) antagonists that inhibit endogenous GnRH signaling by competitively binding to GnRH receptors in the pituitary gland. In 2018, month 7, the drug was approved by the U.S. food and drug administration for the treatment of pain due to endometriosis. In addition, a new indication for Elagolix in combination with low dose hormones for the treatment of severe menstrual bleeding (HMB) associated with uterine fibroids in women is also in clinical trials.
The structural formula of the oxalagogrel key intermediate is as follows:
in patent WO2005007165, 5-bromo-1- [ 2-fluoro-6- (trifluoromethyl) benzyl]-6-methylpyrimidine-2, 4 (1)H,3H) And (3) carrying out alkylation and Suzuki coupling reaction on diketone, then hydrolyzing to remove Boc group, carrying out amino alkylation, and finally hydrolyzing to obtain the oxagolide sodium salt. As shown in the following route, column chromatography is used for purifying the intermediate in the route, and the oxogolide sodium salt is prepared and purified by using a cation exchange column, so that the whole process is too high in cost and is not suitable for industrial production.
Patent CN109651265A proposes the use of (R) -3- (2-amino-2-phenylethyl) -5- (2-fluoro-3-methoxyphenyl) -1- (2-fluoro-6- (trifluoromethyl) benzyl) -6-methylpyrimidine-2, 4 (1)H,3H) Reaction of-diketones with 4-oxobutanoic acid to give oxa-acidsThe final post-treatment of the method, namely the laggolide, adopts column chromatography to purify the product, and the yield is too low.
From the synthesis route of the oxa-rogue, the aim of purifying the product is achieved by passing an intermediate through a column or adopting an ion exchange column when the high-purity oxa-rogue is obtained at present, and the process cost is too expensive due to the operation, so that the large-scale production of the product is not facilitated. Therefore, the method for purifying the oxa-rogue intermediate is developed, and the operation of column chromatography or ion exchange column is reduced, so that the production cost can be greatly reduced, and the method is convenient for industrial large-scale production.
Disclosure of Invention
The invention aims to provide a method for preparing and purifying an oxagoril intermediate salicylate aiming at the defects of the prior art, and the method has the characteristics of simple and convenient operation, low cost, high product purity and yield, and accordance with industrial production.
The invention aims to provide a preparation method of an oxalagogri intermediate salicylate, which adopts the following technical scheme and comprises the following steps:
(1) dissolving the coarse product of the oxagoril intermediate in a solvent, and heating to 30-55 ℃;
(2) dissolving salicylic acid in an alcohol solvent, adding the alcohol solvent into the step (1), and stirring for 1-2 h;
(3) adding water or an alkane solvent into the step (2), stirring for 1-2 hours, and then cooling to room temperature;
(4) separating out solid, and filtering to obtain salicylate of the oxa-golide intermediate.
Preferably, the weight-to-volume ratio of the crude product of the oxalagril intermediate to the solvent in the step (1) is 1: 2-7, and more preferably 1: 3.
Preferably, in step (1), the solvent is methanol, ethanol, isopropanol, acetone, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate, or methyl t-butyl ether, and more preferably isopropyl acetate.
Preferably, the weight volume ratio of the salicylic acid to the alcohol solvent in the step (2) is 1: 1-5, and more preferably 1: 2.
Preferably, the molar weight ratio of the crude product of the oxalagril intermediate to the salicylic acid in the step (2) is 1: 1-1.4, and more preferably 1: 1.2.
Preferably, the alcohol solvent in step (2) is methanol, ethanol, isopropanol, more preferably isopropanol;
preferably, the weight-to-volume ratio of the water or alkane solvent to the crude product of the oxagoril intermediate in the step (3) is 1: 5-10, and further preferably 1: 8;
preferably, the alkane solvent in the step (3) is cyclohexane, n-hexane or n-heptane, more preferably n-heptane;
the invention also provides a method for purifying the salicylate of the oxagoril intermediate, which comprises the following steps:
s-1, dissolving the solid obtained in the step (4) in an ester solvent, adding a 5-10% phosphoric acid water solution to adjust the pH value to 2-3, and extracting and layering to obtain an acid water layer;
s-2, adding the ester solvent in the step S-1 into the acid water layer, adding a 5-10% sodium hydroxide solution to adjust the pH value to 8-9, and extracting and layering to obtain an organic layer;
and (4) concentrating and drying the S-3 organic layer to obtain a refined product of the high-purity Oxagolide intermediate.
Preferably, the volume ratio of the ester solvent to the phosphoric acid aqueous solution in the step S-1 is 1-3: 1, and more preferably 2: 1.
Preferably, the weight-to-volume ratio of the solid to the ester solvent in steps S-1 and S-2 is 1:5 to 15, and more preferably 1: 8.
Preferably, the ester solvent in steps S-1 and S-2 is ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate, and more preferably isopropyl acetate.
Preferably, the volume ratio of the ester solvent to the sodium hydroxide solution in the step S-2 is 2-5: 1, and more preferably 3: 1.
The invention has the beneficial effects that: compared with the traditional method for refining by column chromatography and ion exchange column, the method simplifies the production process of subsequent products and reduces the production cost of the oxagoril sodium salt by preparing and purifying the oxagoril intermediate salicylate, and is suitable for industrial large-scale production. In addition, the method is simple and convenient to operate, the obtained intermediate is low in cost, and the product purity and yield are high.
Drawings
The above advantages and steps of the present invention will become apparent and readily appreciated from the following description of the embodiments taken in conjunction with the accompanying drawings, in which:
fig. 1 is a detection profile of an oxalagril intermediate i before purification according to inventive example 1;
fig. 2 is a detection profile of an oxalagril intermediate i purified according to inventive example 1.
Detailed Description
The present invention will be described in further detail with reference to the following embodiments, and the present invention is not limited to the following examples. Variations and advantages that may occur to those skilled in the art may be incorporated into the invention without departing from the spirit and scope of the inventive concept, and the scope of the appended claims is intended to be protected. The procedures, conditions, reagents, experimental methods and the like for carrying out the present invention are general knowledge and common general knowledge in the art, except for those specifically mentioned below, and the present invention is not particularly limited.
The analytical test instrument was SHIMADZU LC-2030C, the column was Agilent ZORBAX SB-C18, 150mm X4.6 mm, 3.5 μm, the detector was a UV detector, the wavelength was 266nm, the mobile phase A was water and trifluoroacetic acid, the mobile phase B was acetonitrile and trifluoroacetic acid, the elution procedure was 70% mobile phase A and 30% mobile phase B for 0-10min, 10% mobile phase A and 90% mobile phase B for 10-30min, and 70% mobile phase A and 30% mobile phase B for 30-40 min.
Example 1:
dissolving 10g of the oxalagrange intermediate I (purity 87.2%) in 30ml of methanol, heating to 40 ℃, adding a previously dissolved methanol solution of salicylic acid (3 g of salicylic acid in 6ml of methanol), stirring for 1 hour, adding 80ml of water, continuing stirring for 1 hour, then cooling to room temperature, and filtering to obtain 12.4g of the salicylate of the oxalagrange intermediate I. Dissolving the obtained solid in 96ml of ethyl acetate, adding 48ml of 10% phosphoric acid aqueous solution to adjust the pH value to 2, extracting and layering to obtain an acid aqueous layer, adding 96ml of ethyl acetate, adding 32ml of 10% sodium hydroxide solution to adjust the pH value to 9, extracting and layering to obtain an organic layer, and concentrating the organic layer at 45 ℃ until the organic layer is dried to obtain 8.9g of refined product of the intermediate I of the oxalagogrel (the purity is 99.3%).
Example 2:
dissolving 10g of the oxalagrange intermediate I (with the purity of 87.2%) in 30ml of isopropanol, heating to 45 ℃, adding a previously dissolved salicylic acid isopropanol solution (3.2 g of salicylic acid in 9ml of isopropanol), stirring for 1h, adding 50ml of water, continuing stirring for 1h, then cooling to room temperature, and filtering to obtain 11.7g of the salicylate of the oxalagrange intermediate I. Dissolving the obtained solid in 90ml of ethyl acetate, adding 85ml of 5% phosphoric acid aqueous solution to adjust the pH value to 2, extracting and layering to obtain an acid aqueous layer, adding 90ml of ethyl acetate, adding 45ml of 8% sodium hydroxide solution to adjust the pH value to 9, extracting and layering to obtain an organic layer, and concentrating the organic layer at 45 ℃ until the organic layer is dried to obtain 8.5g of refined product of the intermediate I of the oxalagogrel (the purity is 98.9%).
Example 3:
dissolving 10g of the oxadiargyl intermediate I (purity 87.2%) in 20ml of isopropyl acetate, heating to 30 ℃, adding a previously dissolved salicylic acid ethanol solution (3.3 g of salicylic acid in 6ml of ethanol), stirring for 1h, adding 50ml of n-heptane, continuing stirring for 1h, then cooling to room temperature, and filtering to obtain 12.2g of the salicylate of the oxadiargyl intermediate I. Dissolving the obtained solid in 100ml of isopropyl acetate, adding 62.5ml of 8% phosphoric acid aqueous solution to adjust the pH value to 3, extracting and layering to obtain an acid aqueous layer, adding 100ml of isopropyl acetate, adding 28.5ml of 7% sodium hydroxide solution to adjust the pH value to 8, extracting and layering to obtain an organic layer, and concentrating the organic layer at 45 ℃ until the organic layer is dried to obtain 8.8g of refined product of the intermediate I of the oxargoline (the purity is 99.2%).
Example 4:
dissolving 10g of the intermediate II of the oxalagrange (purity 92.3%) in 40ml of acetone, heating to 50 ℃, adding a pre-dissolved isopropanol salicylic acid solution (2.5 g of salicylic acid in 5ml of isopropanol), stirring for 1h, adding 90ml of water, continuing stirring for 1h, then cooling to room temperature, and filtering to obtain 10.8g of the salicylate of the intermediate II of the oxalagrange. Dissolving the obtained solid in 110ml of butyl acetate, adding 91.6ml of 6% phosphoric acid aqueous solution to adjust the pH value to 2, extracting and layering to obtain an acid water layer, adding 110ml of butyl acetate, adding 43.3ml of 6% sodium hydroxide solution to adjust the pH value to 9, extracting and layering to obtain an organic layer, and concentrating the organic layer at 45 ℃ until the organic layer is dried to obtain 9.4g of refined product of the intermediate II of the Oxagolide (purity 99.4%).
Example 5:
dissolving 10g of the oxalagrol intermediate II (with the purity of 92.3%) in 40ml of methyl tert-butyl ether, heating to 30 ℃, adding a previously dissolved salicylic acid isopropanol solution (2.6 g of salicylic acid dissolved in 4ml of isopropanol), stirring for 1h, adding 70ml of cyclohexane, continuing stirring for 1h, then cooling to room temperature, and filtering to obtain 10.3g of the salicylate of the oxalagrol intermediate II. Dissolving the obtained solid in 130ml of isobutyl acetate, adding 62.5ml of 8% phosphoric acid aqueous solution to adjust the pH value to 2, extracting and layering to obtain an acid aqueous layer, adding 130ml of isobutyl acetate, adding 30ml of 10% sodium hydroxide solution to adjust the pH value to 9, extracting and layering to obtain an organic layer, and concentrating the organic layer at 45 ℃ until the organic layer is dried to obtain 9.1g of refined product of the intermediate II of the Oxagolide (purity is 99.1%).
Example 6:
dissolving 10g of the intermediate II of oxalagogrel (purity 92.3%) in 60ml of methanol, heating to 40 ℃, adding a previously dissolved methanol solution of salicylic acid (2.3 g of salicylic acid in 3ml of methanol), stirring for 1 hour, adding 50ml of water, continuing stirring for 1 hour, then cooling to room temperature, and filtering to obtain 9.9g of the salicylate of the intermediate II of oxalagogrel. Dissolving the obtained solid in 120ml of ethyl acetate, adding 45ml of 10% phosphoric acid aqueous solution to adjust the pH value to 3, extracting and layering to obtain an acid aqueous layer, adding 120ml of ethyl acetate, adding 30ml of 9% sodium hydroxide solution to adjust the pH value to 8, extracting and layering to obtain an organic layer, and concentrating the organic layer at 45 ℃ until the organic layer is dried to obtain 8.8g of refined product of the intermediate II of the oxalagogrel (the purity is 99.3%).
Example 7:
10g of the intermediate iii of oxalagril (purity 93.5%) was dissolved in 30ml of methanol, heated to 40 ℃, and then a previously dissolved methanol solution of salicylic acid (2.6 g of salicylic acid in 4ml of methanol) was added thereto, stirred for 1 hour, 70ml of water was added thereto, followed by stirring for 1 hour, then cooled to room temperature, and filtered to obtain 11.5g of the salicylate of the intermediate iii of oxalagril. Dissolving the obtained solid in 88ml of ethyl acetate, adding 50ml of 6% phosphoric acid aqueous solution to adjust the pH value to 2, extracting and layering to obtain an acid aqueous layer, adding 88ml of ethyl acetate, adding 20ml of 10% sodium hydroxide solution to adjust the pH value to 8, extracting and layering to obtain an organic layer, and concentrating the organic layer at 45 ℃ until the organic layer is dried to obtain 9.4g of refined product of the intermediate III of the oxalagogrel (purity of 99.5%).
Example 8:
dissolving 10g of the intermediate III (with the purity of 93.5%) of the oxalagril in 45ml of ethanol, heating to 55 ℃, adding a pre-dissolved ethanol solution of salicylic acid (2.8 g of salicylic acid in 6ml of ethanol), stirring for 1h, adding 100ml of water, continuing stirring for 1h, then cooling to room temperature, and filtering to obtain 11.8g of the salicylate of the intermediate III of the oxalagril. Dissolving the obtained solid in 118ml of isopropyl acetate, adding 35ml of 10% phosphoric acid aqueous solution to adjust the pH value to 2, extracting and layering to obtain an acid aqueous layer, adding 118ml of ethyl acetate, adding 30ml of 10% sodium hydroxide solution to adjust the pH value to 9, extracting and layering to obtain an organic layer, and concentrating the organic layer at 45 ℃ until the organic layer is dried to obtain 9.2g of refined product of the intermediate III of the oxalagogrel (the purity is 99.2%).
Comparative example 1:
the difference from example 1 is that: in the same manner as in example 1, 30ml of methanol was changed to 100ml of methanol to obtain 7.8g of a refined product of intermediate I of oxarogrel (purity: 98.5%).
Comparative example 2:
the difference from example 1 is that: following the same procedure as in example 1, 3g of salicylic acid was changed to 2.5g of salicylic acid to obtain 7.2g of refined product of intermediate I of oxarogrel (purity: 90.6%).
Comparative example 3:
the difference from example 1 is that: in the same manner as in example 1, pH was adjusted to 9 with 32ml of 10% sodium hydroxide solution, and pH was adjusted to 12 with 60ml of 10% sodium hydroxide solution, to thereby obtain 8.1g of refined form of intermediate I of oxalagogri (purity 95.6%).
Claims (13)
1. A preparation method of an oxalagori intermediate salicylate is characterized by comprising the following steps:
(1) dissolving the coarse product of the oxagoril intermediate in a solvent, and heating to 30-55 ℃;
(2) dissolving salicylic acid in an alcohol solvent, adding the alcohol solvent into the step (1), and stirring for 1-2 h;
(3) adding water or an alkane solvent into the step (2), stirring for 1-2 hours, and then cooling to room temperature;
(4) separating out solid, and filtering to obtain salicylate of the oxa-golide intermediate.
2. The method for preparing the oxalagril intermediate salicylate according to claim 1, wherein the weight-to-volume ratio of the crude oxalagril intermediate to the solvent in the step (1) is 1: 2-7.
3. The method for preparing the intermediate salicylate of oxaroglide of claim 1, wherein the solvent in step (1) is one or more selected from methanol, ethanol, isopropanol, acetone, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate and methyl tert-butyl ether.
4. The method for preparing the oxalagril intermediate salicylate according to claim 1, wherein the weight-to-volume ratio of the salicylic acid to the alcohol solvent in the step (2) is 1: 1-5.
5. The method for preparing the oxadary intermediate salicylate according to claim 1, wherein the molar weight ratio of the crude oxadary intermediate to salicylic acid in the step (2) is 1: 1-1.4.
6. The method for preparing the salicylate intermediate of oxalagril according to claim 1, wherein the alcoholic solvent in the step (2) is one or more of methanol, ethanol and isopropanol.
7. The method for preparing the oxadary intermediate salicylate according to claim 1, wherein the weight-to-volume ratio of the water or alkane solvent to the crude oxadary intermediate in the step (3) is 1: 5-10.
8. The method for preparing the oxadary intermediate salicylate according to claim 1, wherein the alkane solvent in the step (3) is one or a mixture of cyclohexane, n-hexane and n-heptane.
9. A method for purifying an oxalagogri intermediate salicylate is characterized by specifically comprising the following steps:
s-1, dissolving the solid obtained in the step (4) in the claim 1 in an ester solvent, adding a 5-10% phosphoric acid water solution to adjust the pH value to 2-3, and extracting and layering to obtain an acid water layer;
s-2, adding the ester solvent in the step S-1 into the acid water layer, adding a 5-10% sodium hydroxide solution to adjust the pH value to 8-9, and extracting and layering to obtain an organic layer;
and (4) concentrating and drying the S-3 organic layer to obtain a refined product of the high-purity Oxagolide intermediate.
10. The method for purifying an oxalagril intermediate salicylate according to claim 9, wherein the volume ratio of the ester solvent to the phosphoric acid aqueous solution in the step S-1 is 1-3: 1.
11. The method for purifying the oxalagril intermediate salicylate of claim 9, wherein the weight to volume ratio of the solid to the ester solvent in steps S-1 and S-2 is 1:5 to 15.
12. The method for purifying an oxa-golide intermediate salicylate of claim 9, wherein the ester solvent in steps S-1 and S-2 is one or more selected from ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, and isobutyl acetate.
13. The method for purifying the oxalagril intermediate salicylate according to claim 9, wherein the volume ratio of the ester solvent to the sodium hydroxide solution in the step S-2 is 2-5: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010039361.2A CN111116490A (en) | 2020-01-15 | 2020-01-15 | Preparation and purification method of oxalagogri intermediate salicylate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010039361.2A CN111116490A (en) | 2020-01-15 | 2020-01-15 | Preparation and purification method of oxalagogri intermediate salicylate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111116490A true CN111116490A (en) | 2020-05-08 |
Family
ID=70490641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010039361.2A Pending CN111116490A (en) | 2020-01-15 | 2020-01-15 | Preparation and purification method of oxalagogri intermediate salicylate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111116490A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111574461A (en) * | 2020-05-29 | 2020-08-25 | 奥锐特药业股份有限公司 | Salt forming purification method of oxalagogrel intermediate and obtained refined oxalagogrel intermediate |
| CN115466224A (en) * | 2021-06-11 | 2022-12-13 | 成都倍特药业股份有限公司 | Salt forming method and purification method of oxalagogri intermediate I |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1819829A (en) * | 2003-07-07 | 2006-08-16 | 纽罗克里生物科学有限公司 | Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| WO2009062087A1 (en) * | 2007-11-07 | 2009-05-14 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| WO2017221144A1 (en) * | 2016-06-20 | 2017-12-28 | Dr. Reddy's Laboratories Limited | Process for the preparation of elagolix sodium and its polymorph |
| CN109956906A (en) * | 2019-04-19 | 2019-07-02 | 奥锐特药业股份有限公司 | A kind of preparation method for disliking La Geli key intermediate |
| CN110204498A (en) * | 2019-06-14 | 2019-09-06 | 奥锐特药业股份有限公司 | A method of it efficiently synthesizes and dislikes La Geli intermediate |
| CN110483415A (en) * | 2019-08-21 | 2019-11-22 | 江苏海岸药业有限公司 | A kind of method for preparing purified for disliking La Geli intermediate |
| EP3572406A1 (en) * | 2018-10-17 | 2019-11-27 | Sandoz Ag | Acid addition salt of elagolix and related compounds |
-
2020
- 2020-01-15 CN CN202010039361.2A patent/CN111116490A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1819829A (en) * | 2003-07-07 | 2006-08-16 | 纽罗克里生物科学有限公司 | Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| WO2009062087A1 (en) * | 2007-11-07 | 2009-05-14 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| WO2017221144A1 (en) * | 2016-06-20 | 2017-12-28 | Dr. Reddy's Laboratories Limited | Process for the preparation of elagolix sodium and its polymorph |
| EP3572406A1 (en) * | 2018-10-17 | 2019-11-27 | Sandoz Ag | Acid addition salt of elagolix and related compounds |
| CN109956906A (en) * | 2019-04-19 | 2019-07-02 | 奥锐特药业股份有限公司 | A kind of preparation method for disliking La Geli key intermediate |
| CN110204498A (en) * | 2019-06-14 | 2019-09-06 | 奥锐特药业股份有限公司 | A method of it efficiently synthesizes and dislikes La Geli intermediate |
| CN110483415A (en) * | 2019-08-21 | 2019-11-22 | 江苏海岸药业有限公司 | A kind of method for preparing purified for disliking La Geli intermediate |
Non-Patent Citations (2)
| Title |
|---|
| STN FILES: "STN检索报告", 《数据库REGISTRY（在线）》 * |
| 来自STN FILES: "《STN检索报告2》", 18 February 2005 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111574461A (en) * | 2020-05-29 | 2020-08-25 | 奥锐特药业股份有限公司 | Salt forming purification method of oxalagogrel intermediate and obtained refined oxalagogrel intermediate |
| CN115466224A (en) * | 2021-06-11 | 2022-12-13 | 成都倍特药业股份有限公司 | Salt forming method and purification method of oxalagogri intermediate I |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110642897B (en) | Preparation method of beta-nicotinamide riboside chloride | |
| US9914697B2 (en) | Methods for making polymorphs of bromfenac sodium and bromfenac sodium formulations | |
| CN111511722B (en) | Method for preparing oxa-goril intermediate and composition thereof | |
| CN111116490A (en) | Preparation and purification method of oxalagogri intermediate salicylate | |
| CN110372609B (en) | Purification method of oxalagogri sodium salt | |
| EP3055295A1 (en) | Synthesis of 1-alkyl-2-amino-imidazol-5-carboxylic acid ester via calpha-substituted n-alkyl-glycine ester derivatives | |
| WO2014187364A1 (en) | Preparation method of trihydroxyethyl rutoside | |
| EP2311794B1 (en) | Polymorphs of bromfenac sodium and methods for preparing bromfenec sodium polymorphs | |
| JP2005507900A (en) | Citalopram manufacturing method | |
| WO2012134392A1 (en) | Process for the production of a pemetrexed salt | |
| WO2017191539A1 (en) | Process for the preparation dl-proline co-crystal of dapagliflozin | |
| CN102485723A (en) | Semi-synthesis of vinpocetine through one kettle way and preparation of water-soluble vinpocetine salt | |
| US20080076825A1 (en) | Novel Crystalline Forms of Entacapone and Production Thereof | |
| CA2805959A1 (en) | Crystals of carboprost tromethamine and the preparation method as well as the uses thereof | |
| CN113185459A (en) | Hydroxychloroquine sulfate and preparation method thereof | |
| CA2032850C (en) | Crystalline magnesium valproate and a method for the preparation thereof | |
| CN108203396B (en) | Synthesis of enkephalinase inhibitor | |
| CN110835349A (en) | Method for preparing α -arteether bulk drug by one-pot method | |
| CN115304537B (en) | Method for preparing 6, 6-dimethyl-3-azabicyclo [3.1.0] hexane | |
| CN103857679A (en) | Methods for the preparation of 5-[2-[7-(trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]ethynyl]-2-pyridinamine | |
| US11613555B2 (en) | Methods for onapristone synthesis dehydration and deprotection | |
| CN105585532B (en) | The post-processing approach of l-ornidazole reaction solution | |
| CN114605483A (en) | Preparation process of icariside I | |
| CN118221681A (en) | Preparation method of allopurinol | |
| CN115490737A (en) | Industrial gastrodin raw material medicine purification method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200508 |
|
| RJ01 | Rejection of invention patent application after publication |